Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Kynmobi was a prescription sublingual film containing apomorphine hydrochloride, a non-ergoline dopamine agonist. It was approved for acute, intermittent treatment of off episodes in patients with Parkinson disease. FDA records now identify Kynmobi as discontinued.
read more about what was kynmobi ...Apomorphine stimulates dopamine receptors. Its effect on Parkinson off episodes is thought to involve stimulation of postsynaptic dopamine D2-type receptors in the caudate-putamen.
Kynmobi was used as needed for acute off episodes in patients with Parkinson disease. Dose initiation and titration occurred under healthcare professional supervision. Concomitant use with 5-HT3 antagonists such as ondansetron, granisetron, dolasetron, or palonosetron was contraindicated due to reports of profound hypotension and loss of consciousness.
The initial dose was 10 mg placed under the tongue. Doses could increase in 5 mg steps until symptom control was reached with acceptable tolerability, within a range of 10 mg to 30 mg. Doses were separated by at least two hours, with no more than five doses per day and no more than 30 mg for a single off episode.
Serious concerns included nausea and vomiting, sudden sleep episodes, somnolence, syncope, orthostatic hypotension, falls, hallucinations, psychotic behavior, impulse-control problems, withdrawal-related fever and confusion, QTc prolongation, and priapism. Oral mucosal irritation also occurred.
Kynmobi treated acute, intermittent off episodes in patients with Parkinson disease.
The initial dose was 10 mg placed under the tongue.
The maximum single dose was 30 mg.
No. FDA records identify Kynmobi as discontinued.
Apomorphine Hydrochloride. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Apomorphine-hydrochloride. Date Accessed October 8, 2026.
Apomorphine Sublingual. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a620044.html. Date Accessed October 8, 2026.
Approved Drug Products with Therapeutic Equivalence Evaluations 46th Edition. U.S. Food and Drug Administration. https://www.fda.gov/media/71474/download. Date Accessed October 8, 2026.
DailyMed - KYNMOBI (apomorphine hydrochloride) sublingual film. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=558399d2-96c6-4bc5-9d44-93b102e4189a. Date Accessed October 8, 2026.
Orange Book July 2023 Changes List. U.S. Food and Drug Administration. https://www.fda.gov/media/171071/download. Date Accessed October 8, 2026.